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Abstract
Drug repurposing for COVID-19 has several potential benefits including shorter develop-
ment time, reduced costs and regulatory support for faster time to market for treatment that
can alleviate the current pandemic. The current study used molecular docking, molecular
dynamics and protein-protein interaction simulations to predict drugs from the Drug Bank
that can bind to the SARS-CoV-2 spike protein interacting surface on the human angioten-
sin-converting enzyme 2 (hACE2) receptor. The study predicted a number of peptide-based
drugs, including Sar9 Met (O2)11-Substance P and BV2, that might bind sufficiently to the
hACE2 receptor to modulate the protein-protein interaction required for infection by the
SARS-CoV-2 virus. Such drugs could be validated in vitro or in vivo as potential inhibitors of
the interaction of SARS-CoV-2 spike protein with the human angiotensin-converting
enzyme 2 (hACE2) in the airway. Exploration of the proposed and current pharmacological
indications of the peptide drugs predicted as potential inhibitors of the interaction between
the spike protein and hACE2 receptor revealed that some of the predicted peptide drugs
have been investigated for the treatment of acute respiratory distress syndrome (ARDS),
viral infection, inflammation and angioedema, and to stimulate the immune system, and
potentiate antiviral agents against influenza virus. Furthermore, these predicted drug hits
may be used as a basis to design new peptide or peptidomimetic drugs with better affinity
and specificity for the hACE2 receptor that may prevent interaction between SARS-CoV-2
spike protein and hACE2 that is prerequisite to the infection by the SARS-CoV-2 virus.
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Introduction
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2, also known as nCOV-2019),
a virus that recently emerged as a human pathogen in the city of Wuhan in China’s Hubei
province, causes fever, severe respiratory illness, and pneumonia [1]. The World Health Orga-
nization (WHO) reported over 17 million confirmed cases globally, leading to at least 680,894
deaths as at 2nd August 2020 [2]. The pathogen was rapidly described as a new member of the
genus betacoronavirus, closely related to many bat coronaviruses and the severe coronavirus
acute respiratory syndrome (SARS-CoV) identified in 2003 [3]. The disease and the virus caus-
ing it were named Coronavirus Disease 2019 (COVID-19) and COVID-19 or the COVID-19
virus, respectively, by WHO [4]. Although many drugs and therapeutics, including hydroxy-
chloroquine, azithromycin [5], remdesivir [6], and idasanutlin [7], are currently being tested
or suggested, no effective prophylactics or therapeutics have yet been identified. This under-
scores the urgency to find the much needed intervention for this global pandemic.
Scientists are gaining insight into the biology of the virus, particularly how it binds with
human respiratory cells through the human angiotensin-converting enzyme 2 (hACE2). The
human angiotensin-converting enzyme 2 (hACE2) plays a role in cardiovascular and renal dis-
ease, diabetes and lung injury [8]. Interestingly, hACE2 has also been shown to be the receptor
for human coronaviruses SARS-CoV, NL63-CoV and SARS-CoV-2 [9]. The hACE2 is a type I
integral membrane glycoprotein orientated with the N-terminus and the catalytic site facing
the extracellular space, where it can metabolize circulating peptides. The small C-terminal,
cytoplasmic domain has a number of potential regulatory sites [10]. It was recently reported
that the virus uses a tightly glycosylated spike (S) protein to pull into host lung cells via hACE2
[11]. The SARS-CoV S protein is a fusion protein with three subdomains consisting of a con-
served core region, a variable or insertion loop and the C-terminal SD-1 domain. Binding of
the SARS-CoV S protein to its receptor, hACE2 requires significant conformational changes
in the S protein. The insertion loop of the S protein has been reported to contain the receptor-
binding domain (RBD) [12]. This is similar to what has been recently reported for the S pro-
tein from SARS-CoV-2 [13]. Although the N-terminal domain (NTD) and a C-terminal
domain (CTD) of the S protein from SARS-CoV-2 can function as a receptor-binding entity,
nonetheless, similar receptor binding modes to hACE2 were observed for SARS-CoV-2-CTD
and SARS-RBD [14]. The critical residues for receptor binding have been identified in the
receptor-binding domain (RBD) of the SARS-CoV S protein and C-terminal SD-1 domain
(CTD) of the SARS-CoV-2 S protein as well as in the interacting partner, hACE2 [15], thus
making them targets for the discovery and development of vaccines and drugs for prevention
and treatment of COVID-19 and other coronavirus infections.
In light of the urgent need for such vaccines and drugs for the COVID-19 pandemic, drug
repurposing becomes an attractive strategy to find known and approved drugs for this new
indication. This approach has gained impetus in medicine, especially in the search for a treat-
ment for complex disorders and pandemics such as COVID-19 [16]. In this study, we con-
ducted a virtual screening (HTVS) of 1070 compounds from the drug bank against interacting
surface on hACE2 receptor to which the SARS-CoV-2 spike protein has been shown to bind
to. The results showed significant binding of a number of approved drugs, experimental and
investigational compounds to the target site. From the top 1070 drugs docked against the inter-
acting surface of the hACE2 receptor, we described two peptide drugs with good predicted
binding affinity and poses that might disrupt the protein-protein interactions between the
SARS-CoV-2 spike protein and the hACE2 receptor. A number of the drugs predicted may be
potentially repurposed for the prevention and treatment of COVID-19.
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Materials and method
Compound library and preparation for molecular docking
The compound library consists of 1070 compounds (these were top ranked compounds cho-
sen from an in house experiment of initial virtual screening of over 7000 compounds from
DrugBank online against spike protein of Human coronavirus HKU1 (HCoV-HKU1)). The
selected compounds were imported into Molecular Operating Environment (MOE) database
viewer. The compounds were prepared by washing (protonation at pH 7, explicit hydrogen
added, 3D coordinates generated), adding partial charges and energy minimized with the
Amber10: EHT force field, down to a RMS gradient of 0.05 kcal/mol/Å2.
Protein target and estimation of its average structure
The protein target was the hACE2 receptor extracted from SARS-CoV-2 spike protein-hCAE2
receptor complex. The crystal structure of receptor-binding domain of the spike (S) glycopro-
tein of SARS-CoV-2 bound to its receptor, hACE2 (6LZG) was downloaded from the RSCB
protein data bank (PDB). We conducted a short molecular dynamics (MD) simulation to
explore the conformational space of the initial model from PDB followed averaging of repre-
sentatives from clusters of the conformers to obtain the average structure of the complex. The
SARS-CoV-2 spike protein was deleted from the complex and the remaining hACE2 receptor
was used for the docking study. The three-dimensional structure of hACE2 receptor was
cleaned, minimized, solvated, and prepared for MD with AMBER forcefield (ff99SB) on the
MDWeb server [17]. The simulation was done over 50 ns with Molecular Operating Environ-
ment (MOE) 2019.01 suite (Molecular Operating Environment (MOE) 2019.01). The average
structure was viewed and compared to the downloaded structure using USCF Chimera [18].
Molecular docking studies
The protein preparation module in Molecular Operating Environment MOE 2019.01(Molecu-
lar Operating Environment (MOE) 2019.01) was used to prepare the average structure hACE2
receptor for virtual screening. The binding site was defined as the interacting surface between
the hACE2 receptor and the SARS-CoV-2 spike protein. Molecular docking simulation was
carried out with the MOE Dock module using the induce-fit model [19]. The hACE2 receptor
was set as ‘Receptor’. The ‘Triangle Matcher’, which is suitable for standard and well-defined
binding sites, was set as the ligand placement method. Thirty poses were generated for each
ligand and the poses were scored according to the London ΔG scoring function. The thirty
poses were taken through molecular mechanics (MM) refinement to get two final poses. The
final docking score was evaluated with the GBVI/WSA ΔG scoring function with the General-
ized Born solvation model (GBVI) [20]. UCSF Chimera [18] was used to visualize the poses.
Molecular dynamics (MD) simulation of hACE2 receptor-ligand complex
The hACE2 receptor with and without a docked ligand (the ligand used here was Sar9 Met
(O2)11-Substance P with a binding free energy of -10.63 kcal/mol) were subjected to molecular
dynamic simulations using the Simulation module in Molecular Operating Environment
MOE 2019.01(Molecular Operating Environment (MOE) 2019.01). The hACE2 receptor and
hACE2 receptor-ligand complex were at different instances protonated and energy minimized
with the MMFF94x force field to get the stable conformer of the protein complexes in a vac-
uum (molecular system). The molecular system was parameterized with “Optimized Potentials
for Liquid Simulations” (OPLS-aa) forcefield, suitable for proteins and small organic mole-
cules. Molecular dynamics simulations were done in three steps. We first heated the molecular
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system to 310 K (37 0C). Then an equilibration step was used to equilibrate the molecule sys-
tem at 310 K (37 0C) for 10 nanoseconds. Next, the simulation step was used to generate the
trajectory of the molecular system at 310 K using the Nose–Poincare–Andersen (NPA) algo-
rithm for 100 nanoseconds (time step of each simulation was set to 0.02 picoseconds). Visuali-
zations and data analysis were performed with VMD software [21].
Simulation and dynamics of SARS-CoV-2 spike protein-hACE2 receptor
interaction
Protein-protein interactions (PPIs), especially between the SARS-CoV-2 spike protein and the
human hACE2 receptor, play an important role in the establishment of the infection by the
SARS-CoV-2 in humans. In this study, PatchDock [22], a free and open accessed web server,
was used to predict and analyze the structures of PPIs between the spike protein and hACE2 in
the presence and absence of one of the top-ranking ligands (BV2) from the docking studies.
FireDock (Mashiach et al., 2008) was used to refine the output from PatchDock and tease out
the various interaction energies involved in the simulated PPIs. Molecular visualization of the
output was done with UCSF Chimera [18]. Following the prediction of the protein-protein
interaction, the SARS-CoV2-hACE2 complexes with and without BV2 were subjected to
molecular dynamic simulations using MOE 2019.01 software as described above.
Results and discussion
Average structure of hACE2 receptor
We conducted a molecular dynamics simulation on the crystal structure downloaded from the
protein data bank, i.e. the SARS-CoV-2 spike protein-hACE2 complex, before separating
hACE2 receptor from the complex for the molecular docking study. Following the molecular
dynamics simulation, the results showed that the average root mean squared fluctuation
(RMSF) per residue of the protein were between 0.30 Å to 1.33 Å (Fig 1). The RMSF per resi-
due is the distance between a residue in the first frame (structure) of the protein under simula-
tion and the same residue in the subsequent frames (structures) of the same protein. Higher
RMSF values indicate greater flexibility during the MD simulation. The highest RMSF value
was observed for Glutamic acid 69 located in the loop region closes to the interacting surface
of hACE2 receptor. Five other residues in hACE2 and four residues in the SARS-CoV-2 spike
protein, located mostly in the loop regions, showed higher fluctuation > 0.8 Å indicative of
some flexibility. However, residues, which constitute the interacting surfaces of the loop region
of the spike protein and the alpha helix region of the hACE2, showed lower flexibility (RMSF
between 0.3 Å and 0.6 Å). Overall RMSF values were higher for a number of residues outside
the interaction surface of the complex than those within the interaction surface. The average
structure of the complex generated from the molecular dynamic simulations was compared to
the downloaded protein data bank (PDB) crystal structure (inserted in Fig 1). The result
showed a root mean square deviation of 0.622 Å between the two complex structures. The
larger RMSF values indicate increased random motions for residues outside the interaction
surface of the complex, and the converse for residues within the interaction surface of the com-
plex. This is a pointer to the involvement of the latter set of residues in the interaction between
the S protein and the hACE2 receptor. In addition, root mean square deviation of 0.622 Å was
observed between the two complex structures These observations suggest potential conforma-
tional changes and moderate flexibility of the S protein and the hACE2 receptor complex.
Hence the need to estimate the average structure of the hACE2 receptor before the molecular
docking studies.
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Molecular docking studies predicted peptide drugs with potential to bind
to the interacting surface of hACE2 receptor
To predict currently approved drugs that will potentially bind to the interacting surface of the
hACE2 receptor, compounds from Drug Bank were docked against this binding site using the
induce-fit model in MOE 2019.01. An induced-fit docking model will capture the ensembles
of the protein conformations which provide relatively high enrichment of the poses of the
docked compounds. The initial London free energy of binding generated for 30 poses were
rescored with generalized Born volume integral (GBVI) model to get the final S score for five
poses. Higher negative S score is a predictor of better ligand interaction with the protein and
more stable the ligand-protein complex. The chemical structures and estimated free energy of
binding (S score) of the top poses of the compounds are presented in S1 Table. The top-
Fig 1. The root mean squared fluctuation (RMSF) per residue plot of the hACE2 receptor obtained from 50 ns molecular dynamics simulation in water at 37 oC (A).
The RMSF per residue measures the average deviation of each protein residue over time from a reference position (i.e. the time-averaged displacement of the protein
residues). Thus, RMSF analysis reveals the degree of fluctuation of portions of the protein. Inserted is the three-dimensional (3D) superimposition of the average
structure of the SARS-CoV-2 S protein and hACE2 receptor complex generated from the molecular dynamics simulation (magenta) and the crystal structure of the
SARS-CoV-2 spike protein and hACE2 complex downloaded from RSCB protein data bank (cyan blue) (B). An average root mean square deviation (RMSD) of 0.622
Å was observed for the complex.
https://doi.org/10.1371/journal.pone.0245258.g001
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ranking compounds based on the predicted S score were mostly peptide-based drugs
(approved, investigational and experimental drugs).
Ligand interactions of six top-ranked drug hits with the hACE2 receptor were generated
(Fig 2). The number of hydrogen bond interactions of the top six ranked drug hits with resi-
dues within the interaction surface of the hACE2 receptor are shown as a heatmap in Fig 3A.
The predicted interactions of peptide drug hits with these amino acid residues that are
involved in the protein-protein interaction between the SARS-CoV-2 spike protein and its
human target (hACE2 receptor) (Fig 3B) might disrupt the protein-protein interaction, thus
limits the infectivity of the virus. Molecular docking of the drug library into the average struc-
ture of hACE2 receptor, which is derived from an average of the multiple conformations of the
hACE2 receptor, provided us with an enrichment of docked compounds with reliable pre-
dicted binding energies/affinities. The molecular docking studies predicted drugs that can
potentially bind strongly to the virus’s spike protein interacting surface on the hACE2
receptor.
Stability analysis of the one of the docked peptide drug-hACE2 receptor
complex
We explored the stability of the predicted interaction between the top ranked peptide drug,
Sar9 Met (O2)11-Substance P, and hACE2 receptor by conducting molecular dynamics of the
system. The stability of the ligand-protein complex system in an aqueous solution was exam-
ined using the parameters RMSD (root mean square deviation) and number of hydrogen
bonds following a 100 ns unconstrained simulation of the docked structure of hACE2 receptor
(bound to Sar9 Met (O2)11-Substance P) and the hACE2 receptor alone.
Fig 2. A 2-dimensional visualization of the ligand-residue interactions of the top poses of six peptide drugs at the interaction surface of the hACE2 receptor.
https://doi.org/10.1371/journal.pone.0245258.g002
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The overall average RSMD for the peptide drug, Sar9 Met (O2)11-Substance P, alone was
3.49 Å and it fluctuated between 3.1 Å and 3.8 Å during the 100 ns simulation. The high flexi-
bility of this ligand alone, suggested by the RSMD, is expected due to the large number of
rotatable bonds in the straight chain structure of this decapeptide. The average RSMD of the
trajectories for the docked complex (peptide drug-hACE2 receptor complex) was 0.049 Å,
which was slightly lower than the RSMD for the hACE2 receptor alone (0.059 Å). The RMSD
of the backbone atoms of the bound and unbound hACE2 receptor showed relative stability
during the simulation (Fig 4A) and the difference in the RSMD of the docked and undocked
hACE2 receptor was 0.01 Å. This suggests that the configurational entropy of the hACE2
receptor backbone might decrease slightly upon binding of Sar9 Met (O2)11-Substance P, thus
attesting to the potential stability of the docked Sar9 Met (O2)11-Substance P and the hACE2
receptor complex.
Fig 3. A heatmap of the count of the hydrogen bond interactions between the six top ranked peptide drugs and amino acid residues
present at the interaction surface of the hACE2 receptor (A). Docked poses of one of the peptide drug hits (BV2) on hACE2 receptor
that might interfere with the protein-protein interaction between the SARS-CoV-2 spike protein and its human target (hACE2
receptor) (B).
https://doi.org/10.1371/journal.pone.0245258.g003
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Heteroatom-hydrogen bonds interactions play a critical role in the formation of protein-
ligand complexes. Regarding stability of the hydrogen bonds (set at donor-acceptor distance of
3.0 Å and angle cutoff of 20o) between docked Sar9 Met (O2)11-Substance P and the hACE2
receptor, the number of hydrogen bonds fluctuated between a minimum of four and a maxi-
mum of thirteen during the 100 ns simulation (Fig 4B). The wide fluctuation of the number of
hydrogen bonds between the docked ligand and hACE2 receptor might be due to the high flex-
ibility of the docked ligand (as evidenced by the high RSMD value of 3.49 Å). This result
revealed the need for a strategy like cyclization to reduce the entropy peptide-based inhibitors
that may be designed for target protein, hACE2 receptor.
Overall, the root-mean-square deviation (RMSD) analyses of hACE2 backbone atoms and
the ligand atomic coordinates as well as the dynamics of the number of hydrogen bonds were
performed to measure the structure stability of the top ranked peptide drug-hACE2 receptor
Fig 4. Top figure shows the plot of RMSD (root mean square deviation) of the interacting surface of hACE2 receptor, in the presence (blue)
and absence (red) of docked Sar9 Met (O2)11-Substance P, against the frames from the simulation. This prediction suggests that there was no
significant change in flexibility or conformation of the interacting surface of hACE2 upon binding of the peptide-drug. Bottom figure shows the
plot of the number of hydrogen bonds between Sar9 Met (O2)11-Substance P and the hACE2 receptor across the frames from the simulation. The
wide fluctuation of the number of hydrogen bonds between the docked ligand and hACE2 receptor might be due to the high flexibility of the
docked ligand (a linear decapeptide).
https://doi.org/10.1371/journal.pone.0245258.g004
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complex. The results suggest that the predicted Sar9 Met (O2)11-Substance P-hACE2 receptor
complex was relatively stable even though the number of hydrogen bonds might fluctuate.
Potential modulation of protein-protein interaction between spike protein
and hACE2 receptor by a docked peptide drug
We hypothesized that the top-ranked peptide drug hits predicted in the study might modulate
the energy of protein-protein interaction between the SARS-CoV-2 spike protein and hACE2
receptor. We conducted a protein-protein docking study to analyze the nature of protein–pro-
tein interactions (PPIs) between SARS-CoV-2 spike protein and human ACE2 receptor in the
absence and presence of a docked peptide drug hits (BV2). The predicted binding free energy
for the top 10 poses from the protein-protein interaction simulation (in the presence and
absence of BV2) were plotted against the respective binding free energies in Fig 5. The pre-
dicted binding free energy between spike protein and hACE2 receptor in the absence of a pep-
tide drug hit was -35.05 kcal/mol for the topmost pose. However, the predicted binding free
energy between spike protein and hACE2 receptor in the presence of a drug hit (BV2)
Fig 5. A plot of the top 10 poses from the spike protein-hACE2 receptor interaction simulation in the presence of docked BV2 (red) and in the absence of
docked BV2 (navy blue) on the x-axis and the binding free energies between the protein-protein interactions on the y-axis.
https://doi.org/10.1371/journal.pone.0245258.g005
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significantly reduced to -17.32 kcal/mol for the top pose. These predictions suggest that BV2
might limit the interaction between the SARS-CoV-2 spike protein and hACE2 receptor.
Structural stability analysis of the predicted protein-protein interaction
between the spike protein-hACE2 receptor
The goal here is to study the stability of the predicted protein-protein interaction between the
SARS-CoV-2 spike protein and hACE2 receptor. We assessed the root mean square of fluctua-
tion (RMSF) of the residues in the protein-protein interacting regions of the two proteins as
well as the root mean squared deviation (RMSD) of the backbone of the protein in the same
regions. Generally, the RMSF value of a residue represents the local flexibility of a protein. It
reflected the mobility of atoms that make up that residue across the trajectories during the MD
simulation. Therefore, higher RMSF values for residues indicate higher mobility (less stability)
of such residues. Similarly, higher RMSD value is an indication of greater flexibility (less stabil-
ity) of the protein backbone. The results for these analyses are presented in Fig 6. The image at
the bottom (Fig 6A) is a plot of the sequence number of the amino acid residues against their
RMSF values for the spike protein-hACE2 complex in the presence of the docked BV2 (red)
and absence of the docked BV2 (navy blue).
It can be observed from this plot that the spike protein-hACE2 complex in the presence of
the docked drug hit (red) showed significant increase in fluctuations of the residues across
most regions of the complex. Particularly, the regions that constitute the interacting surface
between the spike protein (sequence number 1–68) and the hACE2 receptor (sequence num-
ber 716–771) showed great difference in fluctuations of the residues in the presence and
absence of the docked drug. This observation was mirrored by the difference in RMSD of the
backbone of the interacting regions of the protein complex in the presence and absence of the
docked drug hit (shown on the top left (B) and top right (C) of Fig 6). This indicates an
increase in the flexibility of the backbone of the protein in the interacting regions in the pres-
ence of the docked drug hit. The increased fluctuations of residues and flexibility of the protein
backbone observed in the interacting region suggest increased mobility and less stability of the
residues in that region of the complex. This suggests that the docked drug disrupted the stabil-
ity of the spike protein-hACE2 complex by steric and/or electrostatic interference with the
interacting residues that were holding the protein-protein complex together.
One possible explanation for the higher root mean square fluctuation (RMSF) and higher
root mean square deviation (RMSD) of the protein backbone observed in presence of a docked
drug might be the disruption of the erstwhile stable interaction between the SARS-CoV-2
spike protein and the hACE2 receptor by the docked peptide drug. This suggests the hypothe-
sis that the docked drug has the potential to interfere with the interaction of the SARS-CoV-2
spike protein with the hACE2 receptor thus reducing the infectivity of the coronavirus. We
quantify the extent of this potential interference of the interaction of the coronavirus spike
protein with the host receptor by conducting a protein-protein interaction simulation in the
presence and absence of one of the top drugs predicted in this study. The results showed that
there was up to 50% reduction in the binding affinity between the proteins in the presence of
the drug. This suggests the potential of this top ranked peptide drug (BV2), predicted in this
study, to affect the protein-protein interaction required for the infection of the host by the
coronavirus (SARS-CoV-2).
The aim of the current study was to predict drugs from the Drug Bank that can bind to the
interacting surface on the human angiotensin-converting enzyme 2 (hACE2) receptor to
which the SARS-CoV-2 spike protein binds to establish its infection. Such drugs could be fur-
ther studied, validated and repurposed as potential inhibitors of the interaction of coronavirus
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(SARS-CoV-2) with hACE2 receptors in the airway. In comparison to the “de novo” drug dis-
covery process, drug repurposing considerably reduces the cost and time to bring new treat-
ments to the market [23]. This is because the starting point for drug repurposing is the Drug
Bank, which is a pool of approved and experimental drugs with well-documented toxicity,
pharmacology, and drug-drug interactions [24]. In this study, a host of computational strate-
gies and techniques were used to predict peptide drugs that may be potentially validated and
repurposed for the treatment of COVID-19. Molecular docking studies have proven to be a
very effective method for predicting ligand hits in structure-based drug discovery projects
[25]. Molecular dynamics allows the visualization of the motions (flexibility) and stability of
macromolecules involved in binding interactions [26].
Fig 6. Plots from the analysis of the molecular dynamic simulation of the predicted protein-protein interaction between SARS-CoV-2 spike protein-hACE2
receptor complex in the presence and absence of the docked BV2. At the bottom (A), the plot of RMSF and the sequence number of amino acid residues of the spike
protein-hACE2 complex in the presence (red) and absence (navy blue) of the docked BV2 is shown. The interaction surfaces are coloured orange in the model of the
spike protein-hACE2 complex. Top left (B), shows the plot of RMSD of the interacting surface for hACE2 receptor, in the presence (red) and absence (navy blue) of
BV2 within the complex, as a function of simulation time. Top right (C), shows the plot of RMSD of the interacting surface for SARS-CoV-2 spike protein, in the
presence (red) and absence (navy blue) of BV2 within the complex, as a function of simulation time.
https://doi.org/10.1371/journal.pone.0245258.g006
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In all, we predicted that the docked peptide drug hits may provide steric and electrostatic
hindrances to the protein-protein interaction of the SARS-CoV-2 spike protein and the
hACE2 receptor via the C-terminal domain (CTD). We gained insight into the effect of the
binding of one of the top-ranked peptide drugs (BV2) on the dynamics of the protein-protein
interaction (PPI) between the SARS-CoV-2 spike protein and the hACE2 receptor by explor-
ing the PPI with molecular dynamics. We also observed that all of the six top-ranked drug hits
predicted in this study were peptides (biologics). The potential to inhibit protein-protein inter-
actions (PPIs) has been demonstrated by the proliferation of biologics as therapeutic agents,
especially in the treatment of autoimmune diseases [27]. The current indications, basic phar-
macology relevant to COVID-19 and pharmacokinetics of two of the top-ranked peptide
drugs predicted are described in Table 1.
Conclusions
Conclusively, this study predicted peptide-based drugs that could potentially bind sufficiently to
the interacting surface of the hACE2 receptor and could modulate the interaction of the SARS--
CoV-2 spike protein with its host cells. Literature search revealed that the current or investigated
indications for the predicted top-ranked peptide drugs were related to the pathophysiology or
symptoms of COVID-19. Thus, the predicted top-ranked peptide drugs could be validated and
repurposed to prevent and/or treat COVID-19 infection as well as be used as a template for the
design of new peptidomimmetics against the virus. We hope that this drug repurposing hypothe-
sis would stimulate further studies in the quest to find effective treatment for COVID-19.
Supporting information
S1 Table. The chemical structures and binding free energies of the five poses of the top 16
compounds from Drug Bank docked on to hACE2 receptor.
(PDF)






Current indication (s) and comments Status and Pharmacokinetics
1. Sar9 Met (O2)
11-Substance P
-10.63 An analog of the human neuropeptide Substance P that
binds to neurokinin-1 receptor (a transmembrane protein
which can be found throughout the body, including in the
airways of humans and plays an important role in
mediation of local and systemic inflammatory processes)
[24]. It has been investigated for use/treatment in acute
respiratory distress syndrome (ARDS) and viral infection
[24].
An investigational drug. Predictions using the
SWISSADME server [28] revealed that it may have poor
gastrointestinal absorption, no blood-brain barrier (BBB)
penetration, be a P-gp substrate, and may not inhibit
cytochrome P450 enzymes. Therefore, this peptide drug is




-10.55 This is cholera enterotoxin subunit B. The GO term
reported for this peptide (GO: 0046812) revealed that it is
host cell surface binding drug. It interacts selectively and
non-covalently with the surface of a host cell [29]. BV2
has been shown to bind up to five GM1 gangliosides
present on the surface of the intestinal epithelial cells [24].
The foregoing attest to our observation that BV2 has the
potential to bind effectively to hACE2 receptor and such
may prevent protein-protein interaction required for
infection by the COVID-19 virus.
An experimental drug. Although there are no
pharmacokinetic data for this peptide [24], predictions
using the SWISSADME server [28] revealed that it may
have poor gastrointestinal absorption, no blood-brain
barrier (BBB) penetration, be a P-gp substrate, and may not
inhibit cytochrome P450 enzymes. Therefore, this peptide
drug is expected to be administered intravenously,
metabolized by peptidases in the blood and might have low
distribution (concentrated within the vascular circulation)
because it does not penetrate the BBB and may be effluxed
by the P-gp. Prediction showed no tendency for toxicity.
Their binding energy (S score) to the target site (hACE2 receptor), their current status in drug development and pharmacokinetics were also stated.
https://doi.org/10.1371/journal.pone.0245258.t001
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